Search research articles
Contact Us
Filters
Showing results (151-160 of 442) with videos related to
Page
of 45
Sort By:
Investigational New Drugs
|
December 6, 2016
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
Muhammad S Beg, Andrew J Brenner, Jasgit Sachdev, et al.
Journal of Psychiatric Research
|
November 9, 2018
Neuroanatomical abnormalities in fragile X syndrome during the adolescent and young adult years
Gisela M Sandoval, Sehoon Shim, David S Hong, et al.
Frontiers in Immunology
|
November 28, 2022
Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data
Ji Son, Rodney Cheng-En Hsieh, Heather Y Lin, et al.
The Oncologist
|
February 23, 2011
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic
Filip Janku, Apostolia M Tsimberidou, Xuemei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2011
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies
John W Moroney, Matthew P Schlumbrecht, Thorunn Helgason, et al.
Plos One
|
August 11, 2011
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
Filip Janku, J Jack Lee, Apostolia M Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2017
Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs
Diogo D G Bugano, Kenneth Hess, Denis L F Jardim, et al.
Practical Radiation Oncology
|
December 6, 2020
Accreditation Program for Excellence (APEx): A Catalyst for Quality Improvement
David S Hong, Thomas Boike, Samantha Dawes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 10, 2017
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement
Chad Tang, Steven I Sherman, Mellanie Price, et al.
Cancer Chemotherapy and Pharmacology
|
May 14, 2014
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
Johanna C Bendell, David S Hong, Howard A Burris, et al.
Page
of 45
Search research articles
Search
Showing results (151-160 of 442) with videos related to
Sort By:
Page
of 45
Investigational New Drugs
|
December 6, 2016
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
Muhammad S Beg, Andrew J Brenner, Jasgit Sachdev, et al.
Journal of Psychiatric Research
|
November 9, 2018
Neuroanatomical abnormalities in fragile X syndrome during the adolescent and young adult years
Gisela M Sandoval, Sehoon Shim, David S Hong, et al.
Frontiers in Immunology
|
November 28, 2022
Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data
Ji Son, Rodney Cheng-En Hsieh, Heather Y Lin, et al.
The Oncologist
|
February 23, 2011
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic
Filip Janku, Apostolia M Tsimberidou, Xuemei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2011
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies
John W Moroney, Matthew P Schlumbrecht, Thorunn Helgason, et al.
Plos One
|
August 11, 2011
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
Filip Janku, J Jack Lee, Apostolia M Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2017
Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs
Diogo D G Bugano, Kenneth Hess, Denis L F Jardim, et al.
Practical Radiation Oncology
|
December 6, 2020
Accreditation Program for Excellence (APEx): A Catalyst for Quality Improvement
David S Hong, Thomas Boike, Samantha Dawes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 10, 2017
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement
Chad Tang, Steven I Sherman, Mellanie Price, et al.
Cancer Chemotherapy and Pharmacology
|
May 14, 2014
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
Johanna C Bendell, David S Hong, Howard A Burris, et al.
Page
of 45